Democritus University of Thrace (DUTH)
Μελέτη της επίδρασης μεταβολιτών της εντερικής μικροχλωρίδας στις διεργασίες της φλεγμονής και της ίνωσης στις ιδιοπαθείς Φλεγμονώδεις Νόσους του Εντέρου για την δυνητική ανάπτυξη μεταβιοτικών παραγόντων
Abstract
dc:descriptionIntroduction: Inflammatory Bowel Diseases (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing inflammatory disorders of the gastrointestinal tract with a steadily increasing global incidence and a substantial socioeconomic burden. Despite considerable advances in understanding disease pathogenesis and the introduction of biological therapies, the precise mechanisms underlying IBD remain incompletely understood, while a significant proportion of patients fail to achieve sustained clinical remission. Consequently, the identification of novel pathogenic pathways and therapeutic targets remains a major clinical priority. IBD is considered to arise from complex interactions among genetic susceptibility, environmental factors, impaired intestinal epithelial barrier function, dysregulated immune responses, and alterations in the gut microbiota. Intestinal dysbiosis is characterized by reduced microbial diversity, expansion of potentially pathogenic microorganisms, including members of the Proteobacteria phylum, and depletion of beneficial commensals such as Faecalibacterium prausnitzii, collectively contributing to chronic intestinal inflammation through disruption of mucosal homeostasis. Recent research has shifted from describing microbial composition to investigating the gut microbial metabolome, as microbial metabolites constitute the principal mediators of host–microbiota communication. Metabolomic studies have demonstrated profound alterations in fatty acid, bile acid, tryptophan, and amino acid metabolism in both serum and fecal samples from patients with IBD. The biological effects of microbial metabolites are mediated through host metabolite receptors, which are expressed by both intestinal epithelial and immune cells. Activation of these receptors regulates key physiological processes, including maintenance of epithelial barrier integrity, immune cell activation, cytokine production, and immune tolerance. Consequently, impaired MR signaling represents a plausible mechanism through which microbial dysbiosis is translated into chronic intestinal inflammation. A comprehensive understanding of the interactions between the gut microbial metabolome and host metabolite receptors is therefore expected to provide novel insights into IBD pathogenesis while identifying innovative biomarkers and therapeutic targets for precision medicine. Aim and Objectives: The primary aim of this doctoral thesis was to investigate host–microbiota interactions mediated by microbial metabolite receptors (MRs) and to elucidate their contribution to the inflammatory and fibrotic processes underlying IBD, ultimately identifying novel biomarkers and therapeutic targets for postbiotic-based therapeutic approaches. To achieve this objective, the first goal was to comprehensively characterize the expression profile of MRs in the intestinal mucosa and identify differences between patients with IBD and healthy controls through bioinformatic analysis of publicly available RNA-sequencing datasets. Subsequently, receptor expression was integrated with genome-wide differential gene expression analyses to construct co-expression networks and identify the biological pathways associated with each receptor. Following the bioinformatic analyses, the cellular localization of the identified receptors was investigated using transcriptomic deconvolution approaches and subsequently validated experimentally in primary human intestinal subepithelial myofibroblasts and epithelial colonoids. Furthermore, the effects of inflammatory stimulation on receptor expression were examined following exposure to pro-inflammatory cytokines. Finally, the functional consequences of receptor activation were investigated using immortalized human intestinal myofibroblasts stimulated with endogenous receptor agonists under inflammatory conditions, while the fibrotic response was evaluated through collagen production assays. Overall, this thesis aimed to elucidate the contribution of MRs to IBD pathophysiology and identify receptor–metabolite pairs that may serve as future diagnostic biomarkers or therapeutic targets. Materials and Methods: Initially, differential gene expression analysis was performed using publicly available RNA-sequencing datasets. A total of 1,405 intestinal mucosal biopsies were analyzed, including samples from 643 patients with CD, 467 patients with UC, and 295 healthy individuals (HI). Differential expression analysis was conducted using DESeq2 through the RaNA-seq platform, examining differences between patients and healthy controls, inflamed and non-inflamed tissue, and ileal versus colonic mucosa. In addition, an independent dataset from patients with Campylobacter jejuni infection was analyzed to distinguish IBD-specific alterations from those associated with nonspecific intestinal inflammation. Functional characterization included gene co-expression analyses, interaction network construction using Cytoscape, and pathway enrichment analysis using Enrichr. Bioinformatic findings were experimentally validated in intestinal mucosal biopsies obtained from 29 patients with CD, 22 patients with UC, and 14 healthy controls following ethical approval and written informed consent. Target gene expression was quantified by quantitative reverse-transcription polymerase chain reaction (RT-qPCR). Transcriptomic deconvolution was subsequently performed using the xCell algorithm to identify the cellular populations expressing individual MRs. These findings were validated in primary human intestinal subepithelial myofibroblasts and epithelial colonoids isolated from healthy donors using RT-qPCR under both standard and pro-inflammatory conditions, while HCAR2 and HCAR3 protein expression was evaluated by immunofluorescence. To facilitate long-term functional studies, primary human intestinal subepithelial myofibroblasts were immortalized through stable expression of human telomerase reverse transcriptase (hTERT). The immortalized cells were extensively characterized by immunofluorescence, RT-qPCR, scratch wound-healing assays, and collagen production assays. Immortalized myofibroblasts were subsequently stimulated with the endogenous agonists of HCAR2 (nicotinic acid) and HCAR3 (3-hydroxyoctanoic acid) following cytokine pre-stimulation to mimic the inflammatory intestinal microenvironment. Collagen expression was quantified at both mRNA and protein levels using RT-qPCR and the Sircol collagen assay, respectively. Finally, molecular docking simulations between HCAR3 and tryptophan-derived metabolites were performed using PyRx, while ligand–receptor interactions were analyzed using BIOVIA Discovery Studio. Statistical analyses were conducted using R and GraphPad Prism, applying parametric or non-parametric tests as appropriate according to data distribution. Statistical significance was defined as P < 0.05. Results: The present study identified extensive dysregulation of MR expression in IBD, demonstrating that these alterations are determined by disease subtype, inflammatory status, anatomical location, and the cellular composition of the intestinal mucosa. RNA-sequencing analysis revealed that 15 of 105 investigated MRs were differentially expressed between patients with CD, UC and HI. Among these, HCAR2 and HCAR3 exhibited the most pronounced and consistent upregulation in both CD and UC, particularly within inflamed intestinal tissue. Increased expression was also observed for FFAR2, FFAR4, GPR84, S1PR1, and S1PR4, whereas PPARG, NR1H4, CHRM4, TRPV3, TRPV1, NR1I2, and CNR1 were downregulated in specific disease subgroups. Quantitative RT-PCR validation confirmed the majority of the transcriptomic findings, identifying HCAR2, HCAR3, and GPR84 as the most consistently upregulated receptors in IBD. Furthermore, several receptors exhibited marked anatomical specificity between the terminal ileum and colon. Interestingly, some physiological expression differences were lost in patients with IBD, suggesting disruption of the normal spatial organization of MR signaling. Co-expression network analysis demonstrated that HCAR2, HCAR3, and GPR84 function as central hubs within networks of upregulated genes, whereas PPARG and NR1H4 were primarily associated with downregulated genes involved in metabolic and homeostatic pathways. Functional enrichment analysis further revealed that HCAR2, HCAR3, GPR84, and FFAR2 were strongly associated with innate immune processes, including neutrophil chemotaxis, leukocyte activation, and IL-1 signaling, while PPARG and NR1H4 were linked to lipid metabolism, bile acid homeostasis, and other homeostatic functions. Collectively, these findings indicate a shift from homeostatic transcriptional programs toward inflammation-driven signaling networks during IBD. Transcriptomic deconvolution analysis revealed pronounced cell type-specific expression patterns. HCAR2, HCAR3, GPR84, and FFAR2 were predominantly associated with mesenchymal cells and innate immune populations, whereas FFAR4 and PPARG showed preferential association with the intestinal epithelium. These observations were experimentally confirmed using primary human intestinal subepithelial myofibroblasts and epithelial colonoids, in which pro-inflammatory cytokine stimulation induced HCAR2, HCAR3, GPR84, and FFAR2 expression while suppressing PPARG expression. The immortalized intestinal myofibroblasts generated during this study retained the morphological and functional characteristics of primary cells, including comparable collagen production and migratory capacity. Importantly, stimulation with the endogenous HCAR3 agonist 3-hydroxyoctanoic acid significantly increased collagen expression in cytokine-primed myofibroblasts, suggesting a previously unrecognized role for HCAR3 in intestinal fibrosis. Finally, molecular docking simulations demonstrated high binding affinity of HCAR3 for several indole-derived tryptophan metabolites and identified distinct ligand-binding interactions within the receptor binding pocket, supporting HCAR3 as a potential sensor of microbial tryptophan metabolism. Conclusions: This doctoral thesis provides a comprehensive characterization of MR signaling in IBD by integrating large-scale transcriptomic analyses, experimental validation in human tissues, and functional studies in cellular models. The findings demonstrate that MR expression is dynamically regulated according to disease subtype, anatomical location, inflammatory activity, and cellular context. Among the receptors investigated, HCAR2 and HCAR3 emerged as the most consistently dysregulated receptors in IBD, exhibiting strong associations with inflammatory pathways and, notably, with Th17 immune responses. In parallel, several additional receptors—including FFAR2, FFAR4, GPR84, PPARG, NR1H4, NR1I2, and CNR1—were found to participate in distinct signaling networks governing either inflammatory activation or intestinal homeostasis. The study further revealed pronounced compartment-specific expression of MRs between epithelial and mesenchymal cell populations, suggesting the existence of a functionally polarized intestinal microenvironment with respect to microbial metabolite sensing. Moreover, the establishment of an immortalized human intestinal subepithelial myofibroblast cell line provides a valuable experimental platform for investigating fibrosis and host–microbiota interactions. Functional studies demonstrated that HCAR3 activation under inflammatory conditions promotes collagen production, implicating this receptor as a potential mediator linking microbial dysbiosis to intestinal fibrosis. Complementary molecular docking analyses further suggested that HCAR3 may function as a sensor of microbial tryptophan-derived metabolites, thereby connecting alterations in microbial metabolism with host inflammatory responses. Overall, this work substantially advances our understanding of host–microbiota communication in IBD and identifies MRs as key regulators of intestinal inflammation, immune responses, epithelial homeostasis, and fibrogenesis. These findings establish MRs as promising biomarkers of disease activity and progression, while highlighting their potential as therapeutic targets for the development of precision medicine approaches based on modulation of host–microbiota metabolic signaling.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Spathakis, Michail
- Σπαθάκης, Μιχαήλ
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62858